Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Cameron

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Public Health|September 9, 2023
COVID-19 vaccine safety in Scotland - background rates of adverse events of special interestL A Cullen, Z Grange, K Antal, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
The development of novel and selective p56lck tyrosine kinase inhibitorsJ L Bullington, J C Cameron, J E Davis, et al.
Vaccine|August 16, 2005
Costs of running a universal adolescent hepatitis B vaccination programmeL A Wallace, D Young, A Brown, et al.
Lancet (London, England)|December 9, 2021
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trialArabella S V Stuart, Robert H Shaw, Xinxue Liu, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Public Health|September 9, 2023
COVID-19 vaccine safety in Scotland - background rates of adverse events of special interestL A Cullen, Z Grange, K Antal, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
The development of novel and selective p56lck tyrosine kinase inhibitorsJ L Bullington, J C Cameron, J E Davis, et al.
Vaccine|August 16, 2005
Costs of running a universal adolescent hepatitis B vaccination programmeL A Wallace, D Young, A Brown, et al.
Lancet (London, England)|December 9, 2021
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trialArabella S V Stuart, Robert H Shaw, Xinxue Liu, et al.
Pageof 4